Lipvas ASP 20 Capsule is a combination medication containing Atorvastatin 20 mg and Aspirin 75 mg, indicated for the management of cardiovascular risk in patients with hyperlipidemia and those at risk of thrombotic events. Atorvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces elevated low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, thereby decreasing the risk of atherosclerosis and related cardiovascular complications. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to reduced thromboxane A2 production and subsequent inhibition of platelet aggregation, which helps prevent arterial thrombosis. Lipvas ASP 20 is primarily prescribed for secondary prevention of myocardial infarction, stroke, and other cardiovascular events in patients with established coronary artery disease or those at high risk. The combination therapy offers synergistic benefits by addressing both lipid abnormalities and platelet aggregation simultaneously. Patients should use this medication under medical supervision, with appropriate monitoring of lipid profiles, liver function, and bleeding risks. It is contraindicated in individuals with active bleeding, hypersensitivity to either component, or severe liver disease. Caution is advised in patients with a history of peptic ulcer disease or bleeding disorders. Adherence to prescribed dosage and lifestyle modifications is essential for optimal therapeutic outcomes.